TREA

79252849 - FREELINE

Follow

Information

  • Trademark
  • 79252849
  • Serial Number
    79252849
  • Registration Number
    5974485
  • Filing Date
    November 19, 2018
    5 years ago
  • Registration Date
    February 04, 2020
    4 years ago
  • Transaction Date
    February 04, 2023
    a year ago
  • Status Date
    February 04, 2020
    4 years ago
  • Published for Opposition Date
    November 19, 2019
    4 years ago
  • Location Date
    February 04, 2020
    4 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    REGAN, JOHN B
  • Attorney Docket Number
    0641296
    Attorney Name
    Samantha M. Quimby
    Law Office Assigned Location Code
    M40
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
FREELINE
Case File Statements
  • GS0401: Pharmaceutical manufacturing and processing to the order and specification of others; biotechnological or biopharmaceutical manufacturing and processing to the order and specification of others; viral vector production to the order and specification of others; gene therapy manufacturing to the order and specification of others; pharmaceutical formulation to the order and specification of others
  • DM0000: The mark consists of the word "FREELINE" in stylised text.
  • GS0051: Pharmaceutical, medical and veterinary preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for therapeutic or prophylactic purposes in connection with blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for use in treatment, amelioration or prophylaxis of genetic or inherited or non-infectious diseases or disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for treatment, amelioration or prophylaxis of chronic or systemic disease, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders or cancers; pharmaceutical, medical and clinical preparations for use in gene therapy for prevention, amelioration or treatment of disorders, namely of blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases; pharmaceutical, medical and clinical preparations for liver-targeted viral gene therapy; genetic medicines for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious disease; preparations for therapeutic delivery of nucleic acids; viral or nucleic acid vectors for therapeutic or prophylactic purposes or preparations containing such vectors; adeno-associated viral gene therapy preparations for prevention, amelioration or treatment of disorders, namely blood disorders, lysosomal storage disorders, metabolic disorders, inflammatory or immune system disorders, autoimmune disorders, hepatological disorders, central or peripheral nervous system disorders, ocular or ophthalmological disorders, muscular disorders, musculoskeletal disorders, bone disorders, cardiovascular or vascular disorders, endocrine disorders, gastrointestinal disorders, neurological disorders, dermatological disorders, respiratory disorders, urological disorders, cancers or infectious diseases
  • PM0001: FREE LINE
  • CC0000: Color is not claimed as a feature of the mark.
Case File Event Statements
  • 2/4/2023 - a year ago
    28 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH
  • 8/6/2022 - a year ago
    27 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 6/5/2020 - 4 years ago
    26 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 5/18/2020 - 4 years ago
    25 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 5/18/2020 - 4 years ago
    24 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 5/4/2020 - 4 years ago
    23 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 2/4/2020 - 4 years ago
    22 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 11/19/2019 - 4 years ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 11/19/2019 - 4 years ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/15/2019 - 4 years ago
    19 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 10/30/2019 - 4 years ago
    18 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 10/30/2019 - 4 years ago
    17 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 10/30/2019 - 4 years ago
    16 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/17/2019 - 4 years ago
    15 - ASSIGNED TO LIE Type: ALIE
  • 10/10/2019 - 4 years ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/20/2019 - 4 years ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 9/20/2019 - 4 years ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/20/2019 - 4 years ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 4/6/2019 - 5 years ago
    10 - REFUSAL PROCESSED BY IB Type: RFNT
  • 3/21/2019 - 5 years ago
    9 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 3/21/2019 - 5 years ago
    8 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 3/12/2019 - 5 years ago
    7 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 3/11/2019 - 5 years ago
    6 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 3/8/2019 - 5 years ago
    5 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 3/4/2019 - 5 years ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 3/4/2019 - 5 years ago
    3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 3/1/2019 - 5 years ago
    2 - LIMITATION FROM ORIGINAL APPLICATION ENTERED Type: LIMI
  • 2/28/2019 - 5 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR